Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manfred Claassen

Showing results (71-80 of 75) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 75 results.
Journal for Immunotherapy of Cancer|January 20, 2026
Vδ1 T-cell subset appears to be responsive to PD-1 blockade therapy and is associated with survival in melanomaNicola Herold, Jonas Bochem, Johanna Leyens, et al.
Gut|February 18, 2025
Multiomics analysis of immune correlatives in hepatocellular carcinoma patients treated with tremelimumab plus durvalumabYuta Myojin, Sepideh Babaei, Rajiv Trehan, et al.
Cell|August 18, 2023
Tumor-associated macrophages trigger MAIT cell dysfunction at the HCC invasive marginBenjamin Ruf, Matthias Bruhns, Sepideh Babaei, et al.
Journal of Hepatology|May 24, 2023
Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signallingElena Kotsiliti, Valentina Leone, Svenja Schuehle, et al.
Nature|March 25, 2021
NASH limits anti-tumour surveillance in immunotherapy-treated HCCDominik Pfister, Nicolás Gonzalo Núñez, Roser Pinyol, et al.
Pageof 8

Showing results (71-80 of 75) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 75 results.
Journal for Immunotherapy of Cancer|January 20, 2026
Vδ1 T-cell subset appears to be responsive to PD-1 blockade therapy and is associated with survival in melanomaNicola Herold, Jonas Bochem, Johanna Leyens, et al.
Gut|February 18, 2025
Multiomics analysis of immune correlatives in hepatocellular carcinoma patients treated with tremelimumab plus durvalumabYuta Myojin, Sepideh Babaei, Rajiv Trehan, et al.
Cell|August 18, 2023
Tumor-associated macrophages trigger MAIT cell dysfunction at the HCC invasive marginBenjamin Ruf, Matthias Bruhns, Sepideh Babaei, et al.
Journal of Hepatology|May 24, 2023
Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signallingElena Kotsiliti, Valentina Leone, Svenja Schuehle, et al.
Nature|March 25, 2021
NASH limits anti-tumour surveillance in immunotherapy-treated HCCDominik Pfister, Nicolás Gonzalo Núñez, Roser Pinyol, et al.
Pageof 8